{"data":{"type":"company_profile","id":117486,"entity_id":"wefunder:company:117486","attributes":{"canonical_url":"https://wefunder.com/nucleus","generated_at":"2026-06-04T01:17:54Z","updated_at":"2026-06-02T05:01:14Z","entity_ids":{"company":"wefunder:company:117486","slug":"wefunder:company_slug:nucleus"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-04T01:17:54Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-02T05:01:14Z","as_of":"2026-06-04T01:17:54Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-02T05:01:14Z","as_of":"2026-06-04T01:17:54Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-04T01:17:54Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-04T01:17:54Z","confidence":"medium"}}},"company":{"id":117486,"entity_id":"wefunder:company:117486","slug":"nucleus","name":"Nucleus","tagline":"A venture studio for psychedelics","elevator_pitch":"We own and operate assets that connect people with the psychedelics industry.","story":"Nucleus was founded in mid-2021 after Neuly and Psychedelic Invest were purchased by Iter Investments, a prominent venture capital firm investing in the psychedelics industry. In late 2021, the official team was constructed, and Nucleus launched in January 2022 with the mission of connecting people with the psychedelics industry in order to propel psychedelic-assisted therapy forward. Nucleus strives to accomplish this mission by serving the industry as a venture studio building brands that educate the masses, activate new stakeholders, and distribute data about these powerful medicines.1. Declining mental well-being has become the most prevalent long emergency that we’ve all been experiencing.2. Our current pharmaceutical solutions have not proven to be effective enough.3. Studies have continued to reveal just how efficacious psychedelic-assisted therapy can be for a myriad of conditions.Additionally, psychedelics have been growing in popularity. In August alone, over 5 million people around the world searched \"psychedelics\" on Google. The world is curious to learn more about just how helpful psychedelic medicines can be for mental well-being—and rightfully so. Because Nucleus was incubated by Iter Investments, a prominent fund investing in the psychedelics industry, Nucleus is represented by an experienced and well-informed team with deep knowledge and rich connections with stakeholders.The Nucleus team immediately carved out an ecosystem built to serve the companies operating within the industry and developed a hub-and-spoke infrastructure to place Nucleus at the center of future opportunities.With the popular platform Neuly already serving the industry with data, Nucleus set out on a mission to provide more opportunities to any and all stakeholders interacting with the psychedelics industry.After all, stakeholders within the burgeoning psychedelics industry are consistently asking for a reliable source to turn to.Investors are needing data about the public and private markets.Potential patients are searching for more information about these new treatments.Practitioners are looking to reach more patients.Professionals within the industry are seeking new opportunities.Historically, the only resource that could ever encapsulate all of these things in one place has been a well-built tech platform. This is where Nucleus, and the idea of a more robust and flexible venture studio model, comes in.Forward looking projections cannot be guaranteed.Our websites have recently surpassed 100,000 page views per monthOur community has grown to over 50,000 membersIn June, we reached $10,000 in combined monthly revenueWe’ve built the Nucleus infrastructure using an agile hub and spoke model, which makes it easy for third parties to “plug and pull” the data and tools in real time. The layout also allows for more efficient two-way interactions between entities and data points.Zooming out a bit, that’s how the entire Nucleus ecosystem was constructed.The hub and spoke model that powers psychedelic data and technologyThus, this intentionally robust and flexible infrastructure can be leveraged to power:Wellness-related appsby including a psychedelics vertical/experienceService companiesby informing strategies and service models with relevant dataMedia outletsby implementing more cost-effective data capture toolsHealth systemsby onboarding patients and providing data and toolsPhilanthropy/DAOsby raising funds via a blockchain protocolThe Nucleus ecosystem is enriched by Nucleus-owned assetsBecause Nucleus is structured to own a portfolio of assets, all of our brands were built to support our mission. Our brands work together as one large ecosystem that supports each other. Before we explore each brand, though, let's dig into our data asset, Neuly, and how it powers the entire ecosystem (and much of\u0026nbsp;the psychedelics industry).Neuly is a subscription-based data, tools, and dashboard platform.Neuly stores information on psychedelics companies, stakeholders, compounds, clinical trials, patents, legalization, events, jobs, news, and much much more.Neuly distributes this psychedelics-related data\u0026nbsp;through integrations and an APINeuly 2.0 has recently been strengthened with the following features:Drag-and-drop widgets and feeds Customizable data dashboardsIntegrated enterprise, research, media, and investor dashboardsThe ability to find and book treatments and experiences with practitionersA streamlined patient onboarding processA user-owned data infrastructureA team to support requests for an industry report for one low feeA self-serve APIIn addition, Neuly has also introduced “atoms.” These are widely distributed beacons that track changes across the industry in real time. When something we track for the industry gets updated, changed, removed, or otherwise, it enters our database and is then moderated, and subsequently, confirmed by a human before entering the database as a data point.Finally, Neuly has released “Login with Neuly.” This simple yet effective application allows any user of the Neuly platform to move their secure personal data to a third-party site seamlessly via the Neuly API. The goal is to allow for this mobility to save thousands of hours of unnecessary data collection processes as we pave the way to a more streamlined future of data distribution.Using Neuly’s database of practitioners, Nucleus has partnered with PSYC Corporation, a publicly traded media company working in the psychedelics industry.\u0026nbsp;The two companies have come together, via a joint venture, to launch\u0026nbsp;Psychedelic Finder.Neuly powers the database of practitioners across the sitePsyrise powers and supports all intake and communication processesPsychedelic Finder connects those looking for care with the best-matched practitioners, facilitators, and experiences. The website accomplishes this by not only listing approximately 3,000 practitioners on the site but by offering a white glove service to properly match the ‘finder’ with the right ‘healer.’Psychedelic Finder will be launching soon. In the meantime, you can sign up to be notified of the launch.After several months of partnering with ketamine clinics, therapists, and retreats, we knew the demand that we were seeing from those looking for treatment could be better served through a robust platform of activation tools. In other words, we knew we had an opportunity to streamline the onboarding process as more and more people are introduced to these types of treatments. That’s why we transformed Psyrise into an end-to-end marketing platform for mental health brands. Psyrise supports intake processes and marketing/activation funnels for all stakeholders within the ecosystemPsyrise now underpins all of our ecosystem’s onboarding and activation processes. Our practitioner partners now get to benefit from the following tools:Website builderForm builderSurvey builderMarketing/vanity phone numbersSMS communicationsEmail campaignsWorkflow and automation builderSocial media managementReview managementWe plan to continue to slowly roll out the platform for our practitioner partners, narrow the feedback loop, and expand to all clinics, therapists, coaches, and retreats throughout 2023.On top of educating with content, the industry needs more skilled practitioners. Doctors who are looking for ways to integrate psychedelics into their practices will want to know where to go to find the best curricula to train their employees.With Matter Academy, you can find and enroll in the psychedelic course that's right for youThat’s why we used our data to establish a course aggregator. It’s just the beginning, but Matter is the starting point for the journey someone might embark on to gain a more formal education on the world of psychedelics.Neuly powers the database of training courses across the sitePsyrise powers and supports all intake and communication processesOur brand, Psychedelic Invest is one of the most trafficked resources about the business of psychedelics on the web. The website recently surpassed 50,000 page views per month and our subscriber base is quickly approaching 20,000. Subscribers stay informed through our daily content, interviews, reports, and weekly newsletter.Populating market-related data directly from the Neuly databaseA Psychedelics Content NetworkOver the course of 2022, we expanded our content catalog to capture a broader market with branded shows.Below is an example of a recent story we've covered exclusively about one of the largest public companies in the psychedelics industry. This video, not unlike many others we published,\u0026nbsp;received over 2,500 views in 48 hours.\u0026nbsp;The Psychedelic Invest Podcast20 episodesApproximately 5,000 audio downloadsThe Investor HotseatHave interviewed many CEOs in the industryApproximately 10,000 listens and views collectivelyMindshifting MomentsHosted by Margaret WilliamsonExpanding the mind by answering big questions about well-beingWeekly ExtractionsWeekly reviews of the psychedelics market and the companies operating within itHas allowed the Psychedelic Invest YouTube channel to become one of the most popular in the psychedelics industry regarding investmentsBullish vs BearishHosted by Adam TuberoReviews a company or recent event to provide a deep-dive analysis of what’s actually going onOur hub and spoke model, data capture capabilities, and deep industry expertise allows us to build efficient brand-building processes. This has been proven throughout 2022 with the creation of 12 brands that exist within the ecosystem. Our brand creation process is supported by an open culture of wide ideation. With so much going on in psychedelics, it’s important we hear every new idea, assess each one accordingly, and act appropriately when we feel the opportunity outweighs the level of effort. During our own ideation and discovery phases, we’ve confronted dozens of ideas and have acted upon 12 of them. The brands that we have developed thus far span the three types of opportunities that our infrastructure affords us to capitalize on.Buy: As aforementioned, we’ve acquired a few assets.Build: We’ve built many of our brands after architecting the hub-and-spoke infrastructure that is powered by Neuly.Partner: Finally, we’ve formed joint ventures and revenue share agreements to help broaden our reach and collaborate with other entities in the industry.During the development phase, we have the luxury of shelving, pausing, or scaling the businesses we develop. When growth is further pursued, we are able to spin the brand off into its own company and raise outside capital as needed specifically for the growing brand we’ve developed.We’re building brands focused on technology, media, marketing, services, and products.You already know Neuly (data platform), Psychedelic Invest (media), Psyrise (marketing), and Psychedelic Finder (services), but we haven’t told you about everything else we’re building.Oregon Psilocybin Concierge ServicesFound at oregonpsilocybinconcierge.com, OPCS is an exhaustive resource for the upcoming psilocybin-assisted therapy program slated to begin in 2023 in the state of Oregon. OPCS assists potential patients with the necessary resources to enroll while also offering a platform for facilitators to engage.Neuly powers the database of facilitators and training courses across the sitePsyrise powers and supports all intake and communication processesThe Psychedelic SeriesFound at psychedelicseries.com, this collection of panel events has expanded geographically from Miami all the way throughout Europe. With the Psychedelic Series, the events are only getting bigger as demand and curiosity continue to grow.Read all about one of our recent events at Space Park in Miami.\u0026nbsp;Miami is healing through psychedelic medicine.\u0026nbsp;Road to iiiPoints.A recent event in Miami brought about almost 700 likeminded attendeesPsyrise supports stakeholder\u0026nbsp;activation during these eventsParticlesFound at weareparticl.es, Particles is a DAO-based web3 protocol for smart contracts built on the Bitcoin blockchain. With Particles, you can launch tokens, NFTs, and take advantage of decentralized data storage that can eventually overcome today's inefficient healthcare systems.OnchainmindFound at onchainmind.com, OCM is a blog supporting mental health parity through decentralization. Powered by Particles, OCM's mission is to educate the masses about the potential that owning your own health data, especially mental health logs, is the future we should be working toward.Powered by the Particles blockchain protocol7.5% of funds raised will go towards the Wefunder intermediary fee.We have big dreams for Nucleus. And to achieve them, we need more people. That’s where we need you. Your investment will go to growing the Nucleus team in the form of engineers, data analysts, and groups of people to help with education and support.Well, the answer is quite simple.We want our investor base to reflect those actively interested in our mission and drive. We don’t want people who are only interested in lining their pockets with profits.That said, we know your investments are important to you, so we want to make this one count. When you invest in Nucleus, you are investing in our entire ecosystem (remember the ecosystem we mentioned earlier). Additionally, Nucleus gives you the perfect opportunity to diversify your portfolio into the world of psychedelics.Consider Nucleus’s unique structure a one-to-many approach to diversifying your exposure to the psychedelics industry. If you’re excited and optimistic about the future that celebrates the benefits of psychedelic medicines, we encourage you to join the Nucleus familyIf you’d like to journey your way through our assets, we’ve created a checklist of ways you can engage with each of our brands below. We recommend browsing around, kicking the tires, and becoming a part of our ecosystem before you choose to become a part of the family.Request a Demo of Neulyclaim your company’s listing, and start requesting some data.Subscribe to Psychedelic Investread our content and follow the industry.Request a Psyrise Demoand please share the platform with your practitioner friends.Join the Psychedelic Finder Waitlistwe’ll be launching concierge services in December.Attend One of Our EventsRSVP through the Psychedelic Series website.Research a Course With Matterwe’re happy to help you find the course that’s right for you.Join the Oregon Psilocybin Concierge Waitlistkeep track of Measure 109, which introduces psilocybin-assisted therapy in Oregon next year.Join the Particles Communityget introduced to Clarity, Clarinet smart contracts, and how blockchain technology can improve the future.Become a Psychedelics Writerwe’re always looking for more freelance writers.Showcase Your Brand To Our Ecosystemwant to be a guest on one of our shows?are you looking to tell a story?are you promoting something?Welcome aboard!","location":"Fort Lauderdale, FL","website":"https://withnucleus.com","total_amount_raised":517249,"total_investors":130,"is_funded":true,"is_active":true,"quality_score":4,"related_urls":["https://wefunder.com/nucleus","https://withnucleus.com"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/117486/xxl_cropped_nu-cover.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/117486/large_cropped_Nucleus-Business-Card__4_.png","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/117486/standard_cropped_nu-cover.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/117486/standard_cropped_nu-cover.jpg"},"links":{"company_url":"https://withnucleus.com","twitter_url":"http://twitter.com/withnucleus","facebook_url":"https://www.facebook.com/withnucleus","instagram_url":"https://www.instagram.com/withnucleus/"},"highlights":[],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"🤝 A founding team of serial entrepreneurs with multiple exits"},{"index":2,"claim_id":"claim-fact-2","value":"💰 Backed by one of the largest VC firms in the psychedelics industry, Iter Investments"},{"index":3,"claim_id":"claim-fact-3","value":"🔥Well-positioned for the imminent adoption of psychedelic-assisted therapy"},{"index":4,"claim_id":"claim-fact-4","value":"📈A growing audience of approximately 50,000 subscribers, users, and followers"},{"index":5,"claim_id":"claim-fact-5","value":"💸A sales pipeline of approximately 200 psychedelic companies"},{"index":6,"claim_id":"claim-fact-6","value":"👀An expanding content network exceeding 100,000 pageviews per month"},{"index":7,"claim_id":"claim-fact-7","value":"🚀A growing network of approximately 3,000 care practitioners"},{"index":8,"claim_id":"claim-fact-8","value":"⚡️A developing portfolio of 8 brands, with more on the way"}],"team":[{"id":2822316,"entity_id":"wefunder:company_role:2822316","user_entity_id":"wefunder:user:2646470","role":"founder","name":"Logan Lenz","title":"Chief Executive Officer","bio":"Serial marketing and technology entrepreneur Multiple exits Co-contributor to CityCoins Co-contributor to Stacks (smart contracts on Bitcoin) Founding Member of the YEC Co-Founder of Rock 4 Hunger Media planner for Fortune 500s","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/2822316/square_cropped_logan-nucleus.jpg?1665512311","profile_url":"https://wefunder.com/loganlenz3","linkedin_url":"https://linkedin.com/in/loganlenz","twitter_url":"https://twitter.com/loganlenz","related_urls":["https://wefunder.com/loganlenz3"]},{"id":2830918,"entity_id":"wefunder:company_role:2830918","role":"founder","name":"Dustin Robinson","title":"Co-Founder","bio":"Founder at Iter Investments Mr. Cannabis Law Mr. Psychedelic Law University of Florida, Juris Doctorate in Law Masters of Accounting, BA in Accounting","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/2830918/square_cropped_8-1-20_headshot_1.jpg?1665102710","linkedin_url":"https://www.linkedin.com/in/dustin-robinson-esq-cpa-3a48b31a?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAAAQMUWwBsQ2ZAoW0SstZX8x2FyWvj0wlOc8\u0026lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3Ba9EoNwO1Tryulo%2FRmyshSQ%3D%3D","related_urls":[]},{"id":2830919,"entity_id":"wefunder:company_role:2830919","role":"founder","name":"Robert Velarde","title":"Co-Founder","bio":"Founder at Iter Investments Over 25 years of global private equity investment experience Harvard Business School, MBA Northwestern University, BA in Economics","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/2830919/square_cropped_Robert%2BVelarde6780.jpg?1665102706","linkedin_url":"https://www.linkedin.com/in/roberto-velarde-95196019?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAAAPg500BWvBNukyQvRZSTbrzju8HGMIjrbM\u0026lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BFyq%2FeyuRTWmX29M5RrLifA%3D%3D","related_urls":[]},{"id":2830920,"entity_id":"wefunder:company_role:2830920","user_entity_id":"wefunder:user:2651007","role":"founder","name":"Margaret Williamson","title":"Head of Partnerships","bio":"CEO of PRSVR Clothing Over a dozen years of sales experience","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/2830920/square_cropped_margaret.jpg?1665102696","profile_url":"https://wefunder.com/margaretwilliamson","linkedin_url":"https://www.linkedin.com/in/mrsprsvr/","related_urls":["https://wefunder.com/margaretwilliamson"]},{"id":2830922,"entity_id":"wefunder:company_role:2830922","role":"employee","name":"Sydney Alcala","title":"Head of Engineering","bio":"Owner and Operator of development shop Many years of PHP, Laravel, and Wordpress experience","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/2830922/square_cropped_sydney-alcala.jpg?1665102699","linkedin_url":"https://www.linkedin.com/in/sydneyalcala/","related_urls":[]},{"id":2830921,"entity_id":"wefunder:company_role:2830921","role":"employee","name":"Bri Gagliardi","title":"Head of Relationships","bio":"Chief Engagement Officer at Hendrix + Stone Many years of Account Management","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/2830921/square_cropped_bri-gagliardi.jpg?1665102703","linkedin_url":"https://www.linkedin.com/in/brigagliardi/","related_urls":[]}],"featured_investors":[{"id":4530,"entity_id":"wefunder:company_investor_profile:4530","investor_profile_id":2235963,"investor_profile_entity_id":"wefunder:investor_profile:2235963","subject_entity_id":"wefunder:user:2767824","name":"Michelle Weiner","avatar_url":"http://uploads.wefunder.com/uploads/user/avatar/2767824/medium_blob.jpg","profile_url":"https://wefunder.com/michelleweiner2","investment_total":5000,"investment_info":"Invested $5,000 this round","is_lead_investor":true,"related_urls":["https://wefunder.com/michelleweiner2"]}],"investor_memos":[],"tab_counts":{"posts":34,"ask_questions":10,"featured_investors":1,"faq_entries":5},"active_fundraises":[{"id":64877,"entity_id":"wefunder:fundraise:64877","state":"successful","offering_type":"506(b)","funding_type":"note","structure":"ttw","security_type":"equity","currency":"USD","testing_the_waters":true,"min_purchase":200,"max_purchase":9,"funding_target":3000000.0},{"id":75519,"entity_id":"wefunder:fundraise:75519","state":"successful","offering_type":"506(c)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":250000.0,"funding_started_at":"2022-11-23T11:23:39Z","funding_closed_at":"2022-11-23T11:23:40Z"},{"id":64876,"entity_id":"wefunder:fundraise:64876","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":200,"max_purchase":9,"funding_target":500000.0,"funding_started_at":"2022-10-20T20:54:01Z","funding_closed_at":"2023-05-01T04:09:11Z","auto_close_at":"2023-05-01T03:59:59Z"}],"latest_fundraise":{"id":64877,"entity_id":"wefunder:fundraise:64877","state":"successful","offering_type":"506(b)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null,"terms":{"eb":null,"nb":"$12M","txt":"valuation cap"}},"recent_posts":[{"id":236626,"entity_id":"wefunder:feed_item:236626","type":"FeedItem::Update","visibility":"public","title":"Nucleus: 2025 Recap","preview":"It has been far too long since I've provided an update here on Wefunder. I appreciate everyone's patience this year and am pleased to inform you that the lack of updates is solely due to the growth and recent success of our companies.\u0026nbsp;Let's start with 2025 revenues by asset: Neuly: $120,000 Psychedelic Invest: $2,000 Psyrise: $24,000 And we've kept expenses as low as possible. They were as follows for the year (rounded): Neuly: $2,500 Psychedelic Invest: $36,000 Psyrise: $500 Nucleus (Ot...","published_at":"2025-12-28T22:05:22Z","author_name":"Logan Lenz","url":"/feed/236626","canonical_url":"https://wefunder.com/feed/236626"},{"id":176821,"entity_id":"wefunder:feed_item:176821","type":"FeedItem::Update","visibility":"public","title":"Nucleus: Q3 Recap","preview":"Nucleus family,Another quarter is in the books and Nucleus continues to fight through all of the disappointment surrounding the industry we operate in. But we don't want to dwell on the bad stuff. Instead, let's cut right to the chase. We KNOW psychedelic medicines will prosper in the future. But for now, Nucleus must do whatever it can to add value to as many people as possible. This year, that has meant servicing outside of the psychedelics industry. More on that in a little bit...In Q3, we...","published_at":"2024-10-18T08:00:47Z","author_name":"Logan Lenz","url":"/feed/176821","canonical_url":"https://wefunder.com/feed/176821"},{"id":174540,"entity_id":"wefunder:feed_item:174540","type":"FeedItem::Update","visibility":"public","title":"Nucleus: Q2 Update","preview":"Nucleus family,Another quarter is in the books and Nucleus continues to prosper despite all of the uncertainty surrounding it. We've maintained focus on staying lean and generating revenue in order to extend our runway so that we can continue to support the psychedelics industry for as long as possible. I know I keep referencing our goals in these updates, but it's important to understand how we're looking at the health of Nucleus. That's why I'll continue to call out the 4 core main objectiv...","published_at":"2024-07-12T16:39:01Z","author_name":"Logan Lenz","url":"/feed/174540","canonical_url":"https://wefunder.com/feed/174540"},{"id":173961,"entity_id":"wefunder:feed_item:173961","type":"FeedItem::Update","visibility":"public","title":"Nucleus: April \u0026amp; May Update","preview":"Nucleus family,As we approach the end of Q2, I wanted to share a quick update to highlight the last few months for Nucleus. While things continue to go well for Nucleus, the psychedelics industry has been issued a bit of a blow after recent events. For those that don't know, an FDA committee voted to reject Lykos' (formerly MAPS) MDMA for PTSD application. While this did come as a shock to those of us close to the medicines and the outcomes data, it's something that we must accept and learn f...","published_at":"2024-06-11T21:07:18Z","author_name":"Logan Lenz","url":"/feed/173961","canonical_url":"https://wefunder.com/feed/173961"},{"id":172456,"entity_id":"wefunder:feed_item:172456","type":"FeedItem::Update","visibility":"public","title":"Nucleus: A Review of Q1 2024","preview":"Nucleus family,As I mentioned in last month's update, we've narrowed our scope and have maintained a focus on a core set of objectives:Generate as much revenue as possible.Reduce costs to meet revenue (as close to breakeven as possible).Extend runway (to ensure 18-24 months of operations).Innovate with the industry.Although it's been a slow start to the year for the psychedelics industry, I am pleased to share progress and results that reflect the accomplishment of the above goals. Objective ...","published_at":"2024-04-12T19:01:07Z","author_name":"Logan Lenz","url":"/feed/172456","canonical_url":"https://wefunder.com/feed/172456"},{"id":171537,"entity_id":"wefunder:feed_item:171537","type":"FeedItem::Update","visibility":"public","title":"Nucleus: Q1 2024 Update","preview":"Nucleus family,We've recently finished closing our 2023 books and putting together our financial reports for Wefunder. I am pleased to say that Nucleus remains in a stable and promising position given our narrowed burn rate since reducing all expenses in January of this year. The objectives for Nucleus this year are simple:Generate as much revenue as possible.Reduce costs to meet revenue (as close to breakeven as possible).Extend runway to ensure 18-24 months of operations.Innovate with the i...","published_at":"2024-03-15T04:51:31Z","author_name":"Logan Lenz","url":"/feed/171537","canonical_url":"https://wefunder.com/feed/171537"},{"id":169809,"entity_id":"wefunder:feed_item:169809","type":"FeedItem::Update","visibility":"public","title":"Q4 Review/2023 in Review","preview":"Nucleus family,First of all, I hope everyone had a great holiday season and took some time to slow down and enjoy the most wonderful time of year. Also, I'd like to wish everyone a happy new year as we've welcomed another exciting year of purpose-filled work and innovation. I, for one, spent a great deal of my holiday down time mentally navigating all that has changed within the psychedelics industry in 2023. You don't need to look at a chart to recognize how beaten down the sector has been a...","published_at":"2024-01-26T20:12:10Z","author_name":"Logan Lenz","url":"/feed/169809","canonical_url":"https://wefunder.com/feed/169809"},{"id":169082,"entity_id":"wefunder:feed_item:169082","type":"FeedItem::Update","visibility":"public","title":"November Review","preview":"Nucleus family,Fresh off the heels of a busy few weeks of travel and industry growth, I am pleased to share the following monthly update with everyone. As you know, we launched an upgraded version of our data platform Neuly last month\u0026nbsp;(Reminder: You can check out the\u0026nbsp;official press release here). Since then, we've been growing the number of users and streamlining our processes - all with the hopes of developing scalable revenue models.I'll share all of the details below. Neuly.com U...","published_at":"2023-12-05T22:19:05Z","author_name":"Logan Lenz","url":"/feed/169082","canonical_url":"https://wefunder.com/feed/169082"},{"id":168674,"entity_id":"wefunder:feed_item:168674","type":"FeedItem::Update","visibility":"public","title":"October in Review","preview":"Nucleus family,This is the longest I've ever gone without sending a monthly update. For that, I apologize, but because of that, I have a lot of exciting news to share in this update. Things have been moving quite quickly for us following our launch of Neuly 2.0 (Note: You can check out the official press release here). Since the launch, we've engaged with dozens of organizations and welcomed thousands of new users onto the platform. And we're just getting started. The Launch of \"The New Neuly...","published_at":"2023-11-17T03:52:05Z","author_name":"Logan Lenz","url":"/feed/168674","canonical_url":"https://wefunder.com/feed/168674"},{"id":167646,"entity_id":"wefunder:feed_item:167646","type":"FeedItem::Update","visibility":"public","title":"Q3 Recap","preview":"Nucleus family,I am excited to share with you the latest updates on what we're doing at Nucleus along with a Q3 look back to review what we've learned. Nucleus' Ecosystem GrowthIn Q3, our user counts grew 29% across all of our companies. Nucleus (collectively): 15,838 usersNeuly: 3,320 usersPsychedelic Invest: 6,500 subscribersPsyrise: 28 usersNeuly's Soft LaunchLast week, we refreshed neuly.com with a new look, renewed purpose, and an energized model for growth. We're currently soliciting fe...","published_at":"2023-10-06T18:56:35Z","author_name":"Logan Lenz","url":"/feed/167646","canonical_url":"https://wefunder.com/feed/167646"},{"id":166983,"entity_id":"wefunder:feed_item:166983","type":"FeedItem::Update","visibility":"public","title":"August in Review","preview":"Nucleus family,It's time to launch what we're calling Neuly 2.0! Throughout August, we've been hard at work implementing an upgraded version of our vision for our data platform, and it's come to fruition beautifully. Before I say too much too soon (more on Neuly later), I'd like to use this update to talk about Nucleus's assets relative to the current state of the psychedelics industry. Psychedelic InvestPsychedelics vs Big TechAs you know, we keep close tabs on all of our friends doing great...","published_at":"2023-09-08T19:07:32Z","author_name":"Logan Lenz","url":"/feed/166983","canonical_url":"https://wefunder.com/feed/166983"},{"id":166098,"entity_id":"wefunder:feed_item:166098","type":"FeedItem::Update","visibility":"public","title":"Nucleus: July in Review","preview":"Nucleus family,It was a very productive month of July for Nucleus and each of our companies. In this update, I'll review all of the exciting things we have going on right now. It's a new era for Nucleus. Expanded revenue initiatives, refined content processes, and a more cohesive integration between everything we do.First, let's start with our content strategy.Psychedelic Invest: Content StrategyWe welcomed Charley Rose as our very first full-time writer just a few weeks ago. She officially j...","published_at":"2023-08-02T19:23:35Z","author_name":"Logan Lenz","url":"/feed/166098","canonical_url":"https://wefunder.com/feed/166098"},{"id":165428,"entity_id":"wefunder:feed_item:165428","type":"FeedItem::Update","visibility":"public","title":"Q2 Recap","preview":"Nucleus family,It has been an interesting time for the psychedelics industry. While the movement continues to persevere and make progress, economic conditions have made it even harder for companies operating in the space to establish longevity and financial certainty. That said, the overall narrative is improving and the number of people growing and/or healing from psychedelic-assisted therapies is increasing. All the while, Nucleus is maintaining its current positioning across its entities t...","published_at":"2023-07-07T19:08:09Z","author_name":"Logan Lenz","url":"/feed/165428","canonical_url":"https://wefunder.com/feed/165428"},{"id":163826,"entity_id":"wefunder:feed_item:163826","type":"FeedItem::Update","visibility":"public","title":"Nucleus: An Update for May and June","preview":"Logan here. I was fortunate to spend the beginning of May in the Upper Peninsula of Michigan with my family. It was my first real \"vacation\" in a few years. That doesn't mean I completely unplugged, but we had such a great time enjoying our surroundings. It's beautiful there and the trip reinvigorated me. We spent almost all of our time outside and did a great deal of hiking as a family. We even spent an entire day biking around a private island (seen in the image below). Closing the Wefunder...","published_at":"2023-06-12T19:42:46Z","author_name":"Logan Lenz","url":"/feed/163826","canonical_url":"https://wefunder.com/feed/163826"},{"id":163667,"entity_id":"wefunder:feed_item:163667","type":"FeedItem::Update","visibility":"public","title":"Reviewing April and Everything To Come","preview":"The month of April has come to an end so it's a perfect time to reflect on the month. More importantly, it's an opportune moment to prepare for the next growth phase of Nucleus.Community RoundFirst and foremost, we closed the crowdfunding campaign last week at over $520K raised. This capital is precious and shall be treated as such. The goal moving forward is to ensure that\u0026nbsp;every dollar spent yields a return\u0026nbsp;- whether that be in audience, revenue, or a more opaque\u0026nbsp;metric of tec...","published_at":"2023-05-08T05:03:20Z","author_name":"Logan Lenz","url":"/feed/163667","canonical_url":"https://wefunder.com/feed/163667"},{"id":163535,"entity_id":"wefunder:feed_item:163535","type":"FeedItem::Update","visibility":"public","title":"We Did It! Thank You!","preview":"Last night at midnight, our community round closed at $521,349. We are so humbled that 136 of you have shared in our vision of the future enough to come aboard. For those that invested, we'll be going through all of the owed rewards and distributing t-shirts, subscriptions, and passes over the next several weeks.In the meantime, you can expect updates from me often. I want Nucleus to be a shared journey every step of the way. I may be the captain of this ship, but as an important passenger, y...","published_at":"2023-05-01T20:31:33Z","author_name":"Logan Lenz","url":"/feed/163535","canonical_url":"https://wefunder.com/feed/163535"},{"id":163424,"entity_id":"wefunder:feed_item:163424","type":"FeedItem::Update","visibility":"public","title":"$500K Raised (and You Can Still Invest)","preview":"THANK YOU! THANK YOU! THANK YOU!We are ecstatic to announce that we surpassed $500,000 raised on our Wefunder community round. While we were expecting to raise more capital during this round, we are excited to put these funds to work and build flourishing businesses that will support widespread mental health.We have a clear plan that takes us to profitability quickly and the cash injection from this round will serve as the much needed fuel to the Nucleus rocketship that is poised to take-o...","published_at":"2023-04-28T14:49:16Z","author_name":"Logan Lenz","url":"/feed/163424","canonical_url":"https://wefunder.com/feed/163424"},{"id":163388,"entity_id":"wefunder:feed_item:163388","type":"FeedItem::Update","visibility":"public","title":"3 Days Left","preview":"We just surpassed $400K! The investment window is closing. Don't miss out!","published_at":"2023-04-27T17:36:36Z","author_name":"Logan Lenz","url":"/feed/163388","canonical_url":"https://wefunder.com/feed/163388"},{"id":163249,"entity_id":"wefunder:feed_item:163249","type":"FeedItem::Update","visibility":"public","title":"It's the Final Week To Invest in Nucleus","preview":"The end of April is quickly approaching and we will be closing our crowdfunding campaign in less than 7 days. Sunday will be the last day so please don't miss out on your chance to be a part of the Nucleus family.Also, we'd really appreciate it if you help us spread the word. We want to make sure everyone that has interest and can benefit in what we're building at Nucleus is given the opportunity to own a piece of it. So, please tell a friend, post it to your online community, and help us clo...","published_at":"2023-04-24T17:10:12Z","author_name":"Logan Lenz","url":"/feed/163249","canonical_url":"https://wefunder.com/feed/163249"},{"id":163208,"entity_id":"wefunder:feed_item:163208","type":"FeedItem::Update","visibility":"public","title":"Almost $400K Raised and the Final 9 Days","preview":"After announcing last week that we will be closing this Wefunder campaign successfully on April 30th, we have been overwhelmed by the support.We went from $260K to $395K over the last few days alone and there are now only 9 days left to participate.What Else Happened This week?I'm most excited about all of the planned improvements we have in store for our platform, Neuly. As of this week, we have officially inked a deal that will bring in some new resources for product and business developmen...","published_at":"2023-04-21T19:29:56Z","author_name":"Logan Lenz","url":"/feed/163208","canonical_url":"https://wefunder.com/feed/163208"},{"id":162837,"entity_id":"wefunder:feed_item:162837","type":"FeedItem::Update","visibility":"public","title":"13 Days Left Until Nucleus Raises $500K!!!","preview":"Nucleus will be closing its $500,000 raise on April 30th! Nucleus has already raised more than $260,000. And, importantly, Iter Investments has agreed to fund any capital remaining of the $500,000 as of the closing date. Iter Investments is one of the premier funds in the psychedelic and mental health space and is already one of the largest investors in Nucleus. Iter Investment’s Managing Principal Dustin Robinson explains this decision: “Iter Investments is excited for the opportunity to con...","published_at":"2023-04-17T17:21:44Z","author_name":"Logan Lenz","url":"/feed/162837","canonical_url":"https://wefunder.com/feed/162837"},{"id":162267,"entity_id":"wefunder:feed_item:162267","type":"FeedItem::Update","visibility":"public","title":"A Letter from the Captain (Q1 Review)","preview":"Hello,I’m Logan, the Captain (CEO) and Co-Founder of Nucleus. I’ve been receiving a lot of questions lately about the state of the psychedelics industry amidst everything that's going on in the world right now. While it’s too early to know the long-term impact of some of the recent events, the current economic environment has triggered a great deal of concern and uncertainty for the industry we're operating in. In the following update, I'll summarize Nucleus's position and emphasize our forwa...","published_at":"2023-04-11T05:28:01Z","author_name":"Logan Lenz","url":"/feed/162267","canonical_url":"https://wefunder.com/feed/162267"},{"id":161682,"entity_id":"wefunder:feed_item:161682","type":"FeedItem::Update","visibility":"public","title":"Reviewing February (and Looking Ahead)","preview":"It’s\u0026nbsp;already March somehow. As we review the first two months of the year and look ahead to\u0026nbsp;what’s\u0026nbsp;to come, we're motivated by the momentum we continue to build. We're inspired by the impact we are making. And we are humbled by your involvement and commitment to Nucleus's success.In January, we decided to focus on cash flow and building a leaner and profitable set of entities within the Nucleus portfolio. I am pleased to say that this has since resulted in...Nucleus generating ...","published_at":"2023-03-01T16:39:40Z","author_name":"Logan Lenz","url":"/feed/161682","canonical_url":"https://wefunder.com/feed/161682"},{"id":161360,"entity_id":"wefunder:feed_item:161360","type":"FeedItem::Update","visibility":"public","title":"We've Hit $200K!","preview":"We've come a long way but we're only getting started. Thank you to every single one of you that has invested thus far. We look forward to growing this ecosystem with and alongside you every step of the way.If you haven't done so already, please share our crowdfunding campaign with your network. Let's keep going and change the world together!","published_at":"2023-02-16T21:51:35Z","author_name":"Logan Lenz","url":"/feed/161360","canonical_url":"https://wefunder.com/feed/161360"},{"id":161262,"entity_id":"wefunder:feed_item:161262","type":"FeedItem::Update","visibility":"public","title":"How To Get All of Psychedelic Invest's Industry Reports","preview":"All throughout January, Psychedelic Invest has been publishing its industry reports. There are seven to be exact.\u0026nbsp;However, you can only access them if you’re a PRO subscriber. That’s $999 for an annual subscription or $499 per individual report.\u0026nbsp;But since Nucleus is crowdfunding, we figured we’d let our investors become PRO subscribers for nothing. Free.\u0026nbsp;All you have to do is invest in Nucleus here at Wefunder and send an email to logan@withnucleus.com with your name and/or a s...","published_at":"2023-02-13T19:54:50Z","author_name":"Logan Lenz","url":"/feed/161262","canonical_url":"https://wefunder.com/feed/161262"}],"q_and_a":[{"id":223596,"entity_id":"wefunder:comment:223596","question":"How do you envision investors getting a return on their investment? Do you hope to IPO? Have some type of exit?","author_name":"Matthew H","votes":3,"created_at":"2022-10-24T23:55:16Z","canonical_url":"https://wefunder.com/nucleus#question-223596","answers":[{"id":223599,"entity_id":"wefunder:comment:223599","answer":"Hey @MN! Thanks for the question! With our current structure as a venture studio, I have two answers for you. 1. Our Individual Brands Can Be Acquired: Nucleus owns and operates the brands it creates until it doesn't have to anymore. That's when they can spin off on their own, raise their own capital, and establish many liquidation events as they grow on their own. Multiply this process across several successful brands, and Nucleus can unearth a great deal of return for investors along the way. 2. A Nucleus Exit: Our vision is to broaden our efforts to help as many people as possible. The adoption of psychedelics will come with a great deal of opportunity as other industries enter and many of the more prominent players across the healthcare landscape realize they need to figure out their involvement and how they can innovate in this industry. Nucleus will undoubtedly be an attractive acquisition target at that point.","author_name":"Logan Lenz","votes":3,"created_at":"2022-10-25T02:04:57Z"},{"id":225432,"entity_id":"wefunder:comment:225432","answer":"Hi MN! This is a great question! I am the co-founder and board member of Nucleus. I just wanted to add a few comments beyond Logan's below response. Nucleus was founded and funded by my investment firm - Iter Investments. Our fund's time horizon is around 8 years. So, we are fully aligned to create an exit opportunity within the next 3-8 years whether through IPO of Nucleus, acquisition of Nucleus, or acquisitions of some of our other assets. Hopefully, this addresses your question. We look forward to bringing you on board as an investor!","author_name":"Dustin Robinson","votes":2,"created_at":"2022-11-14T18:53:30Z"}]},{"id":243932,"entity_id":"wefunder:comment:243932","question":"Does a personal investment in Nucleus pose any conflict of interest if my company intends to seek capital from you later down the line?","author_name":"Julia Rose M. Polk","votes":2,"created_at":"2023-04-21T00:02:09Z","canonical_url":"https://wefunder.com/nucleus#question-243932","answers":[{"id":243956,"entity_id":"wefunder:comment:243956","answer":"@Julia - Absolutely not! The more ways we can work with you, and for you, the better. Thanks for the question! Looking forward to having you aboard!","author_name":"Logan Lenz","votes":1,"created_at":"2023-04-21T02:47:14Z"}]},{"id":242491,"entity_id":"wefunder:comment:242491","question":"With most psychedelics being illegal in a majority of American states, how do you foresee this affecting the long-term growth of your business?","author_name":"Anthony Bibbs","votes":2,"created_at":"2023-04-11T16:45:37Z","canonical_url":"https://wefunder.com/nucleus#question-242491","answers":[{"id":243337,"entity_id":"wefunder:comment:243337","answer":"While it will be a monumental event and opportunity when psychedelic-assisted therapies become legal and ubiquitous across the country, the businesses we currently operate are far enough away from the substances/medicines themselves for them to be impacted. We don't foresee the regulatory environment getting worse, but as the landscape matures, Nucleus's position should strengthen. Thanks for the question!","author_name":"Logan Lenz","votes":0,"created_at":"2023-04-17T18:38:13Z"}]},{"id":239982,"entity_id":"wefunder:comment:239982","question":"At present, where are you with respect to remaining runway, accounting for rolling closings? If you can't answer that question, then alternatively: How much of this raise have you closed on?","author_name":"Christopher Zusin","votes":2,"created_at":"2023-03-24T16:20:49Z","canonical_url":"https://wefunder.com/nucleus#question-239982","answers":[{"id":242471,"entity_id":"wefunder:comment:242471","answer":"Thanks for the question, Christopher. We have not closed on any of the raised capital yet and are managing cash flow currently with our increases in revenue and what we have in the bank. Once we close the round successfully, we'll be calling all of the capital and will be well-positioned to continue to scale the projects that have already yielded plenty of revenue potential while being bootstrapped.","author_name":"Logan Lenz","votes":0,"created_at":"2023-04-11T14:24:20Z"}]},{"id":233607,"entity_id":"wefunder:comment:233607","question":"1) How big is the global psychedelics market and how much of it do you think you can capture? 2) Is the plan to scale each company in the Nucleus portfolio into a unicorn?","author_name":"Kevin Hardman","votes":2,"created_at":"2023-02-06T17:55:18Z","canonical_url":"https://wefunder.com/nucleus#question-233607","answers":[{"id":235187,"entity_id":"wefunder:comment:235187","answer":"Hey Kevin, Thanks for the questions. 1. Currently valued at half a million, the psychedelics industry is forecasted to reach $8-$11 million by 2028. The sector is growing rapidly and Nucleus will continue to be well-positioned to offer data, marketing, entertainment, and other ancillary services as demand expands. 2. Nucleus has ambitions to establish each individual entity as its own brand servicing the industry accordingly. In that way, every company is structured to scale individually with the goal to grow as much as the market will allow. Please let me know if you have any further questions. Thanks again!","author_name":"Logan Lenz","votes":0,"created_at":"2023-02-16T22:22:44Z"}]},{"id":225378,"entity_id":"wefunder:comment:225378","question":"Would like to invest, but also would like to use that investment to get my foot in the door for a position at this company. Is there room on the team?","author_name":"James Miller","votes":2,"created_at":"2022-11-13T22:33:14Z","canonical_url":"https://wefunder.com/nucleus#question-225378","answers":[{"id":225453,"entity_id":"wefunder:comment:225453","answer":"Hey James, Thanks for the question. As soon as we close this crowdfunding campaign, we will certainly be filling a handful of full-time roles spanning marketing, development, sales, and operations. At that point in time, we'll encourage you to submit your application for the role that's most appropriate for you and your skillset(s). Until then, what better way to stay informed on these future opportunities than to play a role as an active investor in the company? I look forward to welcoming you to the Nucleus family, in one capacity or another.","author_name":"Logan Lenz","votes":0,"created_at":"2022-11-14T20:00:34Z"}]},{"id":245045,"entity_id":"wefunder:comment:245045","question":"not sure what was going on with your video playback buffering or what... wasn't working and I couldn't get it to play.","author_name":"Caleb Hill","votes":1,"created_at":"2023-04-29T07:21:43Z","canonical_url":"https://wefunder.com/nucleus#question-245045","answers":[{"id":245160,"entity_id":"wefunder:comment:245160","answer":"I'm sorry to hear that. Maybe try it again? It could have been a temporary connection issue. :)","author_name":"Logan Lenz","votes":0,"created_at":"2023-04-30T17:45:15Z"}]},{"id":245043,"entity_id":"wefunder:comment:245043","question":"darkportalman.com/War/psychoactive.html (laptop -check link) I'd like help put it forward and make $-? what you think and what do you guys have in the way of some super cool work I could do to help?","author_name":"Caleb Hill","votes":1,"created_at":"2023-04-29T06:54:57Z","canonical_url":"https://wefunder.com/nucleus#question-245043","answers":[{"id":245161,"entity_id":"wefunder:comment:245161","answer":"Hey Caleb, Thanks for your interest! I encourage you to stay connected with the ecosystem we're building. We'll constantly be posting about new opportunities as they arise. Best of luck!","author_name":"Logan Lenz","votes":0,"created_at":"2023-04-30T17:46:49Z"}]},{"id":230843,"entity_id":"wefunder:comment:230843","question":"I went through company's profile but unable to understand how this company is earning money or generating revenue ?","author_name":"Manu KHANDELWAL","votes":1,"created_at":"2023-01-10T15:01:35Z","canonical_url":"https://wefunder.com/nucleus#question-230843","answers":[{"id":231390,"entity_id":"wefunder:comment:231390","answer":"Hey Manu, Thank you for the question! Nucleus is the holding company developing the individual brands that you see laid out in the overview. All revenue that is being generated is coming from those companies. Neuly generates revenue from data subscriptions. Psychedelic Invest earns revenue from paid sponsorships, affiliate sales, and PRO subscribers. Psyrise, which is our fastest-growing asset, is a marketing platform that generates revenue by creating patient and user demand for ketamine clinics, therapists, and retreats. So far in January, $7,500 has been invoiced in total. We expect Psyrise to reach $20,000 in gross monthly revenue before the end of Q1.","author_name":"Logan Lenz","votes":0,"created_at":"2023-01-16T17:45:05Z"}]},{"id":230756,"entity_id":"wefunder:comment:230756","question":"How Nucleus is earning money or generating revenue?","author_name":"Manu KHANDELWAL","votes":1,"created_at":"2023-01-09T15:01:30Z","canonical_url":"https://wefunder.com/nucleus#question-230756","answers":[{"id":231391,"entity_id":"wefunder:comment:231391","answer":"Hey Manu, Thank you for the question! Please see above to the response to your question. I hope that helps. Please let us know if you have any further questions.","author_name":"Logan Lenz","votes":0,"created_at":"2023-01-16T17:45:44Z"}]}],"faq":[{"question":"How do you envision investors getting a return on their investment? Do you hope to IPO? Have some type of exit?","answer":"Hey @MN! Thanks for the question! With our current structure as a venture studio, I have two answers for you. 1. Our Individual Brands Can Be Acquired: Nucleus owns and operates the brands it creates until it doesn't have to anymore. That's when they can spin off on their own, raise their own capital, and establish many liquidation events as they grow on their own. Multiply this process across several successful brands, and Nucleus can unearth a great deal of return for investors along the wa..."},{"question":"Would like to invest, but also would like to use that investment to get my foot in the door for a position at this company. Is there room on the team?","answer":"Hey James, Thanks for the question. As soon as we close this crowdfunding campaign, we will certainly be filling a handful of full-time roles spanning marketing, development, sales, and operations. At that point in time, we'll encourage you to submit your application for the role that's most appropriate for you and your skillset(s). Until then, what better way to stay informed on these future opportunities than to play a role as an active investor in the company? I look forward to welcoming y..."},{"question":"How Nucleus is earning money or generating revenue?","answer":"Hey Manu, Thank you for the question! Please see above to the response to your question. I hope that helps. Please let us know if you have any further questions."},{"question":"I went through company's profile but unable to understand how this company is earning money or generating revenue ?","answer":"Hey Manu, Thank you for the question! Nucleus is the holding company developing the individual brands that you see laid out in the overview. All revenue that is being generated is coming from those companies. Neuly generates revenue from data subscriptions. Psychedelic Invest earns revenue from paid sponsorships, affiliate sales, and PRO subscribers. Psyrise, which is our fastest-growing asset, is a marketing platform that generates revenue by creating patient and user demand for ketamine cli..."},{"question":"1) How big is the global psychedelics market and how much of it do you think you can capture? 2) Is the plan to scale each company in the Nucleus portfolio into a unicorn?","answer":"Hey Kevin, Thanks for the questions. 1. Currently valued at half a million, the psychedelics industry is forecasted to reach $8-$11 million by 2028. The sector is growing rapidly and Nucleus will continue to be well-positioned to offer data, marketing, entertainment, and other ancillary services as demand expands. 2. Nucleus has ambitions to establish each individual entity as its own brand servicing the industry accordingly. In that way, every company is structured to scale individually with..."}]}}}